- Policy
- MFDS imposes fine on imported Nesina Met and Xeomin
- by Lee, Tak-Sun Aug 14, 2020 06:22am
- Takeda Pharmaceuticals Korea’s antidiabetic drug Nesina Met and other imported drugs have received administrative measure from Korea’s Ministry of Food and Drug Safety (MFDS). Specifically for Nesina Met, the importer would be responsible for the health authority’s 30.15 million won fine that substituted a three-month sales ban.
- Company
- Bukwang, registered a patent for COVID-19 tx of Levovir
- by Aug 14, 2020 06:21am
- Bukwang Pharm announced on the 11th that it has registered a patent of COVID-19 of antiviral drug 'Levovir' which is for “Use of L-nucleoside to treat COVID-19”. Bukwang Pharm used Remdesivir as a positive control to confirm the effect in human lung cells. And the company explained that it was also effective in a test conducted on monkey k
- Policy
- Bayer begins development of high-dose of Eylea
- by Lee, Tak-Sun Aug 14, 2020 06:21am
- The competition between Bayer and Novartis for the treatment of age-related macular degeneration (AMD) is intensifying. After Novartis recently received approval in Korea for a new drug 'Beovu', which improved the number of doses, Bayer also began to develop a high-dose of Eylea that extended the dosing period. On the 11th, the MFDS appro
- Policy
- 1 out of 8 Koreans prescribed with narcotic anti-anxiety
- by Lee, Tak-Sun Aug 14, 2020 06:21am
- In last year alone, one out of eight people in South Korea have been prescribed with narcotic anti-anxiety medications. On Aug. 12, Ministry of Food and Drug Safety (MFDS) informed a pamphlet on ‘Safe Use of Narcotic Anti-anxiety Medication’ would be disseminated with the relevant information found from its big data analysis on the use of
- Policy
- The right age to use KRW 2.5 billion SMA drug Zolgensma
- by Lee, Tak-Sun Aug 13, 2020 06:27am
- Prior to the South Korean health authority’s approval on Zolgensma, known as the most expensive drug in the world, Central Pharmaceutical Affairs Deliberation Committee discussed the appropriate age of the drug user. The manufacturer Novartis has applied for an indication to treat patients under the age of two, but the committee conclud
- Company
- Kynteles is added in the revision of the domestic guidelines
- by Eo, Yun-Ho Aug 13, 2020 06:25am
- Kynteles is expected to be recommended as the first line therapy in the domestic IBD guidelines. Kim Joo-sung, president of the KASID( Department of Gastroenterology, SNUH), guided domestically at a press conference to commemorate the expansion of insurance coverage for the first-line treatment of Inflammatory Bowel Disease (IBD) of Takeda
- Policy
- There are 13 COVID-19 treatments in domestic clinical trials
- by Lee, Tak-Sun Aug 13, 2020 06:25am
- Currently, there are 9 antiviral drugs and 4 immunomodulatory drugs for COVID-19 treatments currently in clinical trials in Korea. As antiviral drugs and immunomodulatory drugs have different mechanisms of action, treatment methods are also different. The MFDS said that two clinical trials (Rebif, GX-I7) were added since the announcement on J
- Policy
- 74% relying on imported substance at risk amid COVID-19
- by Lee, Jeong-Hwan Aug 13, 2020 06:25am
- While the domestic self-sufficiency of pharmaceutical substance has been constantly falling and 74 percent of the industry is relying on overseas-imported substances, experts warn the South Korean pharmaceutical industry may be at risk when the substance supply gets unstable amid COVID-19. They advise the Korean government should set
- Company
- Quadrivalent Flu Vaccine for NIP, failed in bidding
- by Aug 13, 2020 06:25am
- The procurement of a tetravalent vaccine for influenza for NIP failed bidding three times due to an excessively low unit price. According to related industries on the 10th, two bids for the '2020-2021 season influenza vaccine purchase' conducted by the KCDC were failed on the 28th of last month. Initially, New Medipharm and PharmWorld (NIP
- Company
- Big 5 pass Qsymia powered by Alvogen-CKD co-marketing
- by Eo, Yun-Ho Aug 12, 2020 06:00am
- The Big Five general hospitals have cleared the prescription of Qsymia speedily widening its brand awareness within the obesity treatment market. According to pharmaceutical industry sources, the drug committees at Big Five hospitals like Seoul National University Hospital, Severance Hospital, Samsung Seoul Medical Center and Seoul Asan
